Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fisher Asset Management LLC, managed by Ken Fisher, recently executed a significant transaction involving Eli Lilly And Company ((LLY)). The hedge fund increased its position by 153,265 shares.
Recent Updates on Eli Lilly And Company stock
Eli Lilly (LLY) has advanced multiple eloralintide (LY3841136) programs, including new Phase 3 trials in obesity, obstructive sleep apnea, and knee osteoarthritis pain, plus a completed Phase 1 combo study with tirzepatide that supports further obesity work. The company also updated a recruiting Phase 2 trial of solbinsiran for severe hypertriglyceridemia, reinforcing its broader cardiometabolic pipeline and long-term growth story, though near-term stock impact is expected to be modest.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
The score is driven primarily by strong profitability and upbeat 2026 guidance (large projected revenue/EPS growth and continued product/pipeline momentum). Offsetting factors are weak cash-flow metrics and high leverage, while technicals are currently bearish and valuation remains expensive with a low dividend yield.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly And Company
YTD Price Performance: -2.79%
Average Trading Volume: 3,415,810
Current Market Cap: $1000.4B